title: Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: implications for gene therapy.
abstract: Grafting of saphenous vein (SV) conduits into the arterial circulation triggers a number of adaptive pathological changes characterized by progressive medial thickening, neointima formation and accelerated atheroma. Previous studies have shown that modification of vein graft biology is possible by adenovirus (Ad)-mediated gene transfer, although gene expression is transient. Advancement of vascular gene therapy to the clinic is compromised by the lack of safe and efficient vector systems that provide sustained therapeutic gene delivery to the vasculature. Due to inadequacies of both Ad and adeno-associated virus (AAV) serotype-2 (AAV-2) systems, we have evaluated gene delivery to endothelial cells (ECs) and smooth muscle cells (SMCs) using alternate AAV serotypes and a third-generation vesicular stomatis virus glycoprotein-pseudotyped lentiviral system. Transduction of both primary human SV EC and SMC was lower using all alternate AAV serotypes compared to AAV-2. However, transduction of both cell types by lentivirus was efficient even at clinically relevant exposure times (15 min), was without toxicity and was promoter sensitive. Transduction levels at lower doses were further enhanced with the addition of the surfactant Poloxamer-407 (P-407). Direct comparison with Ad and AAV-2 confirmed the unique potential for this system. Moreover, we constructed and overexpressed the therapeutic gene tissue inhibitor of metalloproteinase-3 (TIMP-3) using lentivirus and demonstrated transgene production comparable to Ad with concomitant blockade of SMC migration and induction of cell death. We have demonstrated for the first time the potential for third-generation lentiviral vectors, but not alternate AAV serotypes, as efficient vascular gene delivery vectors.
authors.affiliation: Division of Cardiovascular and Medical Sciences, University of Glasgow, Church Street, G11 6NT, Glasgow, UK.
authors.forename: Kate L
authors.initials: KL
authors.lastname: Dishart
authors.forename: Laura
authors.initials: L
authors.lastname: Denby
authors.forename: Sarah J
authors.initials: SJ
authors.lastname: George
authors.forename: Stuart A
authors.initials: SA
authors.lastname: Nicklin
authors.forename: Satya
authors.initials: S
authors.lastname: Yendluri
authors.forename: Melanie J
authors.initials: MJ
authors.lastname: Tuerk
authors.forename: Michael P
authors.initials: MP
authors.lastname: Kelley
authors.forename: Brian A
authors.initials: BA
authors.lastname: Donahue
authors.forename: Andrew C
authors.initials: AC
authors.lastname: Newby
authors.forename: Thomas
authors.initials: T
authors.lastname: Harding
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Baker
mesh_terms: D002319:Cardiovascular System / Q000378:metabolism*; D000229:Dependovirus; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D016086:Lentivirus; D014161:Transduction, Genetic; D014721:Vesicular stomatitis Indiana virus